Sanofi Extends Blueprint Medicines Tender Offer Period
Sanofi announced an extension of its tender offer to purchase Blueprint Medicines shares, now set to expire on July 17, 2025. The offer remains subject to certain conditions.
Paris – Sanofi announced on July 17, 2025, that its wholly owned subsidiary, Rothko Merger Sub, Inc., has extended the expiration date for its tender offer to acquire all outstanding shares of Blueprint Medicines Corporation. The offer will now expire on July 17, 2025, at 5:00 PM EDST.
The acquisition proposal offers $129.00 in cash per share, along with one contractual contingent right per share. This contingent right provides the potential for additional cash payments of up to $6.00 per share, contingent upon the achievement of specified milestones.
As of 11:59 PM EDST on July 16, 2025, approximately 45.85% of Blueprint's outstanding shares had been tendered and not withdrawn. An additional 36.08% were tendered via notices of guaranteed delivery, though these are not yet considered validly tendered for meeting the minimum condition.
Sanofi's offer is contingent on the fulfillment of several conditions, including the tender of a majority of Blueprint's common stock. The terms of the offer are detailed in the offer to purchase documents filed with the U.S. Securities and Exchange Commission.